Incyte extends its rally, shares outpace biotech peers
28.06.2026 - 11:18:04 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 11:17.
Incyte (US45337C1027) stands out on NASDAQ with a strong one-year performance that has lifted the shares markedly. A recent Simply Wall St analysis highlights that the stock has rallied around 66 percent over the past twelve months, yet still trades on valuation multiples below many biotech peers on the same exchange according to a Simply Wall St article syndicated via Yahoo Finance.
What recent analyses say
In the Simply Wall St framework, Incyte currently carries a valuation score of 2 out of 6, indicating that the stock is not seen as aggressively priced despite the marked share-price gains over the last year per the same Simply Wall St-based report. The analysis notes that Incyte trades on a price-to-earnings ratio of roughly 15.9 times, which stands below both the broader biotech industry average of about 17.2 times and a selected peer group average near 25.6 times, suggesting a comparatively muted valuation against sector peers on NASDAQ.
Alongside the conventional P/E multiple, Simply Wall St also calculates a proprietary "Fair Ratio" of around 12.5 times for Incyte, a metric designed to blend growth expectations and risk into a single comparative indicator as outlined in the valuation commentary. Even after the shares’ strong rally, that fair ratio sits below the peer-group average in the biotech space, underlining how the stock is still described as trading at a discount to some comparable names despite its robust price performance over the last twelve months.
How consensus and targets look
On the consensus side, MarketBeat data point to an average analyst price target for Incyte shares of about 107.85 US dollars, implying a potential downside of just over 5 percent from the latest closing levels around 113.75 dollars as of June 26, 2026 based on MarketBeat’s competitor and target overview. This configuration marks the stock as one where the market price has moved above the central sell-side target band, a pattern that often reflects either cautious analyst assumptions or a faster-than-expected improvement in investor sentiment.
Additional commentary from Intellectia.ai, citing Benzinga as the source, notes that Truist recently raised its price target on Incyte to 105 dollars from 103 dollars while maintaining a Hold rating on the shares ahead of upcoming quarterly earnings according to the Truist preview quoted via Benzinga. In that update, Truist’s analyst points to adjustments in the firm’s model following the Vega acquisition and an updated build for von Willebrand’s disease indications, as well as a recent CMS reimbursement win with Opzelura, illustrating how pipeline dynamics and reimbursement milestones continue to shape the valuation debate around the Incyte stock.
Further background and data on the Incyte shares
For more Incyte news, price data and regulatory filings, the ad-hoc-news topic page and the company’s investor-relations site offer additional context on the NASDAQ-listed biotech.
The business behind the stock
Incyte generates its revenue primarily through a portfolio of oncology and inflammation therapies, with the JAK1/JAK2 inhibitor ruxolitinib, marketed as Jakafi in the United States, serving as a core commercial asset in myelofibrosis and polycythemia vera. Beyond Jakafi, the company develops and commercializes additional targeted therapies, including Opzelura, a topical ruxolitinib formulation approved in indications such as atopic dermatitis and vitiligo, and partners on several other molecules through licensing and co-development arrangements, anchoring a long-term strategy focused on hematology and dermatology.
Where the shares trade today
The Incyte shares (US45337C1027) most recently closed on NASDAQ at 113.75 US dollars as of 2026-06-26, 16:00 Eastern Time, reflecting a 5.78 percent gain on that session compared with the prior close and placing the company’s equity value clearly above the current consensus analyst target band.
Key data on the Incyte shares
- Company: Incyte Corporation
- ISIN: US45337C1027
- WKN: 896133
- Ticker: INCY
- Trading venue: NASDAQ
- Price (as of 2026-06-26, 16:00): 113.75 USD
- Market cap: 25.3 billion USD (as of 2026-06-26)
- Sector / industry: Biotechnology / Pharmaceuticals
- Index membership: NASDAQ Biotechnology Index
- Next earnings date: 2026-07-30
This article is for informational purposes only and does not contain investment advice, personalized recommendations or an offer to buy or sell securities. All data are based on sources deemed reliable at the time of review but may change without notice. Investors should conduct their own research or consult a qualified advisor before making investment decisions.
